Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Chronic postsurgical pain affects women long after cesarean delivery

25

Sep 2026

Chronic postsurgical pain affects women long after cesarean delivery

A new synthesis of global evidence, published in Anaesthesia (the journal of the Association of Anaesthetists), finds that chronic postsurgical pain after cesarean delivery is associated with substantial impairment in women's quality of life and everyday functioning in the months and years after giving birth.

Intuitive eating may be linked to more than a healthier relationship with food

25

Sep 2026

Intuitive eating may be linked to more than a healthier relationship with food

A cross-sectional study of 1,057 U.S. adults examined how intuitive eating relates to stress, sleep, physical activity, substance use, diet, self-rated health, and self-reported cardiometabolic conditions. Higher intuitive eating scores were associated with several favorable health indicators, although the study cannot establish causality or determine the direction of these relationships.

Why are more younger adults in the Eastern Mediterranean facing colorectal cancer?

24

Sep 2026

Why are more younger adults in the Eastern Mediterranean facing colorectal cancer?

A 22-country analysis of modeled GLOBOCAN 2022 data found 15,381 early-onset colorectal cancer cases and 6,965 related deaths across the WHO Eastern Mediterranean Region, with substantial differences between countries and comparatively high mortality. Projections suggest that annual case and death counts could rise markedly by 2050, largely due to demographic change, while the findings support screening and detection strategies tailored to local resources and disease burden.

The heart effects of antidepressants may depend as much on the patient as the drug

24

Sep 2026

The heart effects of antidepressants may depend as much on the patient as the drug

Antidepressants differed in their effects on QTc, with amitriptyline and escitalopram producing small average increases, and the magnitude of changes varying according to individual patient characteristics. The trials did not detect an increase in early major cardiovascular events or non-suicidal sudden death, but they were not large or long enough to rule out rare or later cardiovascular events.

AI model predicts immunotherapy-related pneumonitis risk from CT scans

24

Sep 2026

AI model predicts immunotherapy-related pneumonitis risk from CT scans

Researchers at The University of Texas MD Anderson Cancer Center have developed an artificial intelligence (AI) model that can identify lung cancer patients at increased risk of developing a serious immunotherapy-related side effect before treatment begins, offering a possible path toward more personalized monitoring and prevention strategies.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.